Clene Reports Promising NfL Biomarker Data for ALS Hopeful

Clene has announced positive results from the HEALEY ALS Platform Trial, revealing that CNM-Au8 led to significant reductions in plasma neurofilament light chain concentrations in patients with amyotrophic lateral sclerosis (ALS). The company is considering filing a New Drug Application and preparing the complete CNM-Au8 clinical data package for regulatory discussions with the FDA. Developed us..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 19.
  • textsms

Biogen Teams with NeuroSense to Explore ALS Neurofilament Biomarker

Biogen has partnered with NeuroSense Therapeutics to conduct a study on the effects of PrimeC on neurofilament levels in patients with ALS. The study will be funded by Biogen and use blood samples from 69 PARADIGM patients provided by NeuroSense. The collaboration includes data sharing and joint evaluation of correlations among endpoints. PrimeC is an investigational combination therapeutic comp..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 15.
  • textsms